Mitargos
Mitargos, a seed-stage biotech, is developing MG-001, an oral treatment that targets the root causes of brain damage by restoring mitochondrial bioenergetics. Focused on traumatic brain injury (TBI) and Alzheimer’s disease (AD), MG-001 aims to boost bioenergetics, enhancing mitochondria to support healing and resilience. Mitargos strives to transform health with a patient-centered, de-risked approach, offering hope to a field weighed down by setbacks and breaking the cycle of fear and hopelessness with fresh possibilities.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Mitargos
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Mitargos
1 distinct titles indexed · top 1 shown.
- 1chief medical officer
Sign up to unlock all 1 contacts at Mitargos
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Mitargos
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.